Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
Enochian BioSciences (NASDAQ: ENOB) received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to delayed filings of Form 10-Q for the period ended December 31, 2022. This follows previous notices for not filing its Annual Report on Form 10-K and Quarterly Report for September 30, 2022, resulting in ongoing non-compliance. Although there is no immediate effect on its listing status, failure to comply by April 11, 2023, may result in delisting. The company has submitted a plan to regain compliance, which has been accepted by Nasdaq.
- The company has a plan accepted by Nasdaq to regain compliance with its filing obligations.
- There is currently no immediate impact on the listing status of the company’s shares.
- Ongoing non-compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filings.
- Risk of delisting if compliance is not achieved by April 11, 2023.
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended December 31, 2022 (the "Form 10-Q"), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Company received notices from Nasdaq indicating that as a result of not having timely filed its Annual Report on Form 10-K for the period ended June 30, 2022 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the period ended September 30, 2022, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1).
This notification has no immediate effect on the listing of the Company’s shares on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company’s common stock will be subject to delisting from Nasdaq.
As previously reported on Form 8-K, Nasdaq accepted the Company’s plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) and therefore the Company has 180 calendar days from the due date of the Form 10-K, or April 11, 2023, to regain compliance, and file the Form 10-K and Form 10-Qs for the periods ended September 30, 2022 and December 31, 2022.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Source: Enochian Biosciences Inc.
FAQ
What happened to Enochian BioSciences on February 16, 2023?
What is the deadline for Enochian BioSciences to regain compliance?
Is there an immediate effect on Enochian BioSciences' stock due to the notice?
What forms is Enochian BioSciences required to file to comply with Nasdaq?
What are the consequences if Enochian BioSciences fails to meet the compliance deadline?
